[The treatment strategy of H. pylori infection and the new triple therapy].
The strategies against H. pylori infection have been developed very fast. Since the efficacy of mono-therapy (one antimicrobial drug) and dual-therapy (proton-pump inhibitor (PPI) + one antimicrobial drug) were not good, and the safety of classical triple therapy (bismuth + two antimicrobial drugs) was bad, new triple-therapy consisted with PPI + two antimicrobial drugs is considered as a standard regimen of the treatment of H. pylori infection. However there are several questions about this new strategy which we have to answer. The first question is how can we diagnose the cure of H. pylori infection and when we should do it? The second one is which statistical method should we choose for evaluating the success rate? The third one is which drug should we use and how long should the patient continuing to have the drug? A lot of scientific research are need to clarify these questions.
Third Department of Internal Medicine, Kyorin University School of Medicine.
S
S
Hoshiya
S
S
Takahashi
K
K
Tokunaga
S
S
Saito
D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination / Q000008:administration & dosage*; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000382:microbiology; D016480:Helicobacter pylori / Q000302:isolation & purification; D006801:Humans; D009853:Omeprazole / Q000008:administration & dosage*; D054328:Proton Pump Inhibitors
D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D054328:Proton Pump Inhibitors; D009853:Omeprazole